Journey Medical Corp.’s DFD-29, partnered with Dr. Reddy's Laboratories Ltd., has potential to claim a significant share of the papulopustular rosacea market, which Galderma S.A.’s Oracea (doxycycline) currently dominates, having originally won US Food and Drug Administration approval in 1967. Topline results from Phase III clinical trials showed a statistically significant efficacy advantage for the drug over both Oracea and placebo in terms of reducing lesion count in adult patients with the skin condition.
Journey announced results from the MVOR-1 and MVOR-2 trials on 11 July, stating that both achieved their co-primary endpoints of...